Health Care Startup Outro Secures $7M in Funding

Outro, a NYC-based provider of an integrated deprescribing platform helping people safely discontinue psychiatric medications, has secured $7 million in funding across Pre-Seed and Seed rounds.

The round saw backers including Listen Ventures, Cake Ventures, Jason Calacanis’s LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group, Pave Health Ventures, and others.

The company plans to use the funding to expand its clinician network, develop AI tools for deprescribing, extend its tapering model to additional drug classes, and grow partnerships with universities and advocacy groups.

What is Outro?

Outro provides an integrated deprescribing platform designed to help people safely reduce or discontinue medication's under clinical supervision. The company initially focuses on antidepressants.

Read More:Hammes Appoints Patrick Hammes as Chief Executive Officer

Its model combines specially trained clinicians, evidence-informed tapering protocols, patient monitoring, psychosocial support, and technology built for medication discontinuation.

Deprescribing can be complex because patients may experience withdrawal symptoms and require different approaches depending on their circumstances. Outro aims to give patients and clinicians structured support throughout the process.

How Much Funding Has Outro Raised?

Outro has raised $7 million across its Pre-Seed and Seed funding rounds.

The source does not provide a breakdown of the amount raised in each round or details of the dates of previous investments.

Who Invested in Outro’s Funding Rounds?

Outro’s backers include:

• Listen Ventures
• Cake Ventures
• LAUNCH, founded by Jason Calacanis
• Actions Capital
• Hannah Grey VC
• SemperVirens
• Brock Recovery Group
• Pave Health Ventures
• Other investors

Why the Funding Matters

Outro will use the funding to expand its network of deprescribing clinicians and further develop AI applications for deprescribing-specific workflows.

The company also plans to extend its tapering model to additional drug classes and expand existing partnerships with universities and advocacy groups.

These efforts are aimed at increasing access to structured, clinically supported medication discontinuation services.

Who founded Outro?

Outro was founded in 2022 by Mark Horowitz and Brandon Goode.

Horowitz is a researcher focused on deprescribing, while Goode is a health technology entrepreneur. The company is headquartered in New York City.

"Deprescribing guidance has existed in countries like the U.K. for years," says Dr. Mark Horowitz, Outro's co-founder and one of the world's leading researchers on safely stopping psychiatric medications. "Yet in America, where antidepressant use is widespread, tapering support is very hard to come by, so millions of patients are left without support when they are ready to come off.

"Only a few years ago, it was considered taboo to even talk openly about mental health," says Brandon Goode, co-founder and CEO of Outro. "Today, patients are asking a different question: if starting medication deserves support, why does stopping often happen without it? We’ve built the on-ramp for medications.

Market and Business Growth

Outro's flagship Taper Management program is currently available in 14 states.

The company is initially focused on antidepressants, which are widely used in the United States. According to the source, approximately one in six Americans takes an antidepressant, and average use has extended beyond five years.

Outro aims to address the lack of structured support for people considering whether and how to discontinue psychiatric medication. Its platform combines clinical care, tapering protocols, monitoring and psychosocial support.

What Happens Next?

Outro plans to expand its clinician network, improve its AI-supported deprescribing workflows, and extend its tapering model to additional drug classes.

The company will also continue developing partnerships with universities and advocacy groups as it expands access to its Taper Management program.

Read More:Tim Heidel Co-Founded Veir Raises $110M in Series C Funding